Acromegaly is typically caused by a growth hormone–secreting pituitary adenoma, driving
excess secretion of insulin-like growth factor 1. Acromegaly may result in a variety of …

Acromegaly (ACM) is a chronic, progressive disorder caused by the persistent
hypersecretion of GH, in the vast majority of cases secreted by a pituitary adenoma. The …

Aim To gather data regarding factors predicting responsiveness to pasireotide in
acromegaly. Patients and methods SSTR2a, SSTR3, SSTR5, AIP, Ki-67 and the adenoma …

Acromegaly is associated with high morbidity and elevated mortality when not adequately
treated. Surgery is the first-line treatment for most patients as it is the only one that can lead …

Acromegaly is associated with significant morbidity and mortality if it is not appropriately
treated. In addition to insulin-like growth factor 1 and growth hormone normalization as well …

The delay in controlling the disease in patients who do not respond to first-line treatment
with first generation somatostatin receptor ligands (first-generation SRLs) can be quantified …

Pharmacologic treatment of acromegaly is currently based upon assay-error strategy, the
first-generation somatostatin receptor ligands (SRL) being the first-line treatment. However …

Acromegaly is a chronic disease with an increased mortality in case of persistently active
disease. The treatment of acromegaly is mainly based on the surgical resection of the GH …

Context Medical treatment of acromegaly is currently performed through a trial-and-error
approach using first-generation somatostatin receptor ligands (fgSRLs) as first-line drugs …

Objective: To clarify the selection of medical therapy following transsphenoidal surgery in
patients with acromegaly, based on growth hormone (GH)/insulin-like growth factor 1 (IGF-1) …